NEW YORK (GenomeWeb News) – Agilent Technologies has signed a co-marketing agreement with Life Technologies related to targeted resequencing, an Agilent official said today.

Speaking at the UBS Global Life Sciences Conference, Nick Roelofs, president of Agilent's Life Sciences Group, said that the company has signed an agreement with Life Technologies to co-market Agilent's SureSelect Target Enrichment System with the Applied Biosystems SOLiD sequencing system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.